SLG
RARE icon

Stanley-Laman Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Stanley-Laman Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,080
Closed -$259K – 275
2019
Q2 		$259K Buy
+4,080
New +$260K 0.06% 242

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stanley-Laman Group's RARE Position: Q3 2019 in Review

Stanley-Laman Group sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2019, closing a stake of 4,080 shares — an estimated $259K sold.

Stanley-Laman Group first reported a position in RARE in Q2 2019 and held it in 1 quarter. The position peaked at $259K in Q2 2019. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2019.

  • Stanley-Laman Group reported no remaining Ultragenyx Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 4,080 Ultragenyx Pharmaceutical shares in Q3 2019, an estimated $259K.
  • Stanley-Laman Group first reported a position in Ultragenyx Pharmaceutical in Q2 2019 and held it in 1 quarter.
  • Stanley-Laman Group's Ultragenyx Pharmaceutical position peaked at $259K in Q2 2019.
  • 172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2019.

Based on Stanley-Laman Group's 13F filing for Q3 2019, filed 8 Nov 2019.